



Author Correction: Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity

Correction to: *Nature Communications*
<https://doi.org/10.1038/ncomms10787>,
published online 23 February 2016

<https://doi.org/10.1038/s41467-023-36239-z>

Published online: 03 February 2023



Ricardo Sant'Anna, Pablo Gallego, Lei Z. Robinson, Alda Pereira-Henriques, Nelson Ferreira, Francisca Pinheiro, Sebastian Esperante, Irantzu Pallares, Oscar Huertas, Maria Rosário Almeida, Natàlia Reixach, Raul Insa, Adrian Velazquez-Campoy, David Reverter, Núria Reig & Salvador Ventura

The original version of this Article contained the following errors:

The original version of this Article contained an error in the legend of Fig. 5c, which incorrectly omitted the following: 'Please note that the same control was published in a previous article⁶⁵ that reported the results obtained for other inhibitors of L55P-TTR aggregation that were tested in the same dot blot assay.' This error has been corrected in both the PDF and HTML versions of the Article.

The original version of this Article omitted a reference to previous work in 'Ferreira, N. et al. Molecular Tweezers Targeting Transthyretin Amyloidosis. *Neurotherapeutics* **11**, 450–461 (2014)'. This has been added as reference 65 in the legend of Fig. 5c, as described above. This error has been corrected in both the PDF and HTML versions of the Article.

In addition, the original version of the Supplementary Information associated with this Article contained errors in Supplementary Fig. 8, which showed an incomplete dot blot and was accompanied by an incomplete legend, which incorrectly read 'Selected images of the dot blot used in main figure 5c.' The correct version of the legend states 'Uncropped blot for results shown in Figure 5c. Several compounds (including tolcapone, tafamidis, EGCG and CLR01) were tested in the same dot blot assay as potential inhibitors of L55P-TTR aggregation, sharing the same controls (no inhibitor) on an acetate cellulose membrane. Figure 5c showed the results obtained for the control, tolcapone and tafamidis, while a previous article showed the results obtained for the control, CLR01 and EGCG: Ferreira, N. et al. Molecular Tweezers Targeting Transthyretin Amyloidosis. *Neurotherapeutics* **11**, 450–461 (2014)'. The HTML has been updated to include a corrected version of the Supplementary Information; the original incorrect version of Supplementary Fig. 8 can be found as Supplementary Information associated with this Correction.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41467-023-36239-z>.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023